Cat. No.: | PRODRP00073 |
Size: | |
Quantity: |
|
Pricey: | Inquiry |
Source: | Escherichia coli |
Molecular Weight: | Approximately 8.1 kDa, a single non-glycosylated polypeptide chain containing 71 amino acids. |
AA Sequence: | ARGTNVGREC CLKYFKGAIP LRKLKTWYQT SEDCSRDAIV FVTVQNKAIC SDPNDKKVKK ALKYLQSLER S |
Purity: | > 97% by SDS-PAGE and HPLC analyses. |
Biological Activity: | Fully biologically active when compared to standard. The biological activity determined by a chemotaxis bioassay using human T-lymphocytes is in a concentration range of 1.0-10 ng/mL. |
Physical Appearance: | Sterile filtered white lyophilized (freeze-dried) powder. |
Formulation: | Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, 300 mM NaCl, pH7.4, with 0.02% Tween-20. |
Endotoxin: | Less than 0.1 EU/μg of rRhTARC/CCL17 as determined by LAL method. |
Reconstitution: | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month, 2 to 8°C under sterile conditions after reconstitution. 3 months, -20 to -70°C under sterile conditions after reconstitution. |
Background: | CCL17, also known as thymus and activation-related chemokine (TARC), is produced from the CCL17 gene. It is consistently expressed by thymus cells and temporarily by phytohemagglutinin-stimulated peripheral blood mononuclear cells. CCL17 functions through chemokine receptors CCR4 and CCR8, attracting T lymphocytes and other leukocytes. Its significance extends to skin disorders such as atopic dermatitis, bullous pemphigoid, and mycosis fungoides. CCL17 shares amino acid sequence similarities of approximately 24-29% with RANTES, MIP-1α, MIP-1β, MCP-1, MCP-2, MCP-3, and I-309. |